United Therapeutics Announces Publication of ADVANCE OUTCOMES Study in The Lancet; Ralinepag Remains Investigational for PAH

Music Beats Cancer Launches “Thumbs Up for a Cure” to Support the Next Generation of Childhood Cancer Treatments

Music Beats Cancer, a nonprofit supporting cancer-fighting biotechnologies, will host its inaugural 'Thumbs Up for a Cure' event on September 5 at LongHouse Reserve in East Hampton. The event brings together families, biotech innovators, philanthropists, and artists to advance childhood cancer treatments. A unique Kids Q&A will feature children evaluating promising technologies from biotech companies developing treatments for difficult-to-treat pediatric cancers including DIPG.

United Therapeutics Announces FDA Accepted NDA For Ralinepag In Pulmonary Arterial Hypertension, With PDUFA Target Action Date Of June 24, 2027

United Therapeutics Announces Full Enrollment Of TETON-PPF Study Evaluating Use Of Tyvaso Inhalation Solution For Treatment Of Progressive Pulmonary Fibrosis; Topline Data Expected In H2 Of 2027

Approximately 200,000 patients in the United States have PPF, with limited treatment optionsTopline data expected in the second half of 2027United Therapeutics Corporation (Nasdaq: UTHR) announced full enrollment of its

RBC Capital Maintains Outperform on United Therapeutics, Lowers Price Target to $677

RBC Capital analyst Lisa Walter maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and lowers the price target from $704 to $677.